Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-11-14
2006-11-14
Nashed, Nashaat T. (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S069100, C514S012200, C514S885000
Reexamination Certificate
active
07135452
ABSTRACT:
Recombinant surfactant protein A and pharmaceutical compositions based thereon are useful for the prevention or treatment of pulmonary infection and inflammation.
REFERENCES:
patent: 5840527 (1998-11-01), Schilling, Jr. et al.
patent: 6267958 (2001-07-01), Andya et al.
patent: 0 652 011 (1995-05-01), None
Borron et al. Surfactant protein A inhibits T cell proliferation via its collagen-like tail and a 210-kDa receptor. Oct. 1998, Am. J. Physiol. vol. 275 (Lung Cell. Mol. Physiol. 19) pp. L679-L686.
McCormack et al. The Structure and Function of Surfactant Protein A. 1994, vol. 269, No. 8, pp. 5833-5841.
Nicholson, A.E. Predicting Stability of Lyophilized Products. (1976) Dev. Biol. Stand. vol. 36, pp. 69-75.
Harrod, Kevin S., et al., “SP-A enhances viral clearance and inhibits inflammation after pulmonary adenoviral infection”.American Journal Physiology, vol. 277, No. 3 part 1, L580-L588, 1999.
Hartshorn, Kevan L., et al., “Evidence for a Protective Role of Pulmonary Surfactant Protein D (SP-D) against Influenza A Viruses”.Journal of Clinical Investigation, vol. 94, No. 1, 311-319, 1994.
LeVine, Ann Marie, et al., “Surfactant Protein-A-Deficient Mice Are Susceptible toPseudomonas aeruginosaInfection”.American Journal of Respiratory Cell and Molecular Biology, vol. 19, No. 4, 700-708, Oct. 1998.
Griese, M., “Pulmonary surfactant in health and human lung diseases: states of the art.”European Respiratory Journal. 13:1455-1476, 1999.
LeVine, A.M. et al., “Surfactant Protein-A (SP-A) Binds Group BStreptococcus(GBS) Enhancing Phagocytosis and Clearance from Lungs of SP-A Deficient Mice.”J. Resp. Crit. Care Med.vol. 157, A865, 1998.
Madan, T. et al. “Lung surfactant proteins A and D can inhibit specific IgE binding to the allergens ofAspergillus fumigatusand block allergen-induced histamine release from human basophils.”Clin. Exp. Immunol.vol. 110, pp. 241-249, 1997.
King, R.J. “Pulmonary surfactant.”J. Appl. Physiol.: Respirat. Environ. Exercise Physiol.vol. 53(1), pp. 1-8, 1982.
Wang, Jiu-Yao et al. “Inhibitory Effect of Pulmonary Surfactant Proteins A and D on Allergen-induced Lymphocyte Proliferation and Histamine Release in Children with Asthma.”Am. J. Respir. Crit. Care Med.vol. 158, pp. 510-518, 1998.
King, R.J. et al. “Surfactant Protein-A Deficiency in a Primate Model of Bronchopulmonary Dysplasia”Am. J. Respir. Crit. Care Med.vol. 151, pp. 1989-1997, 1995.
LeVine, A.M. et al. “Surfactant Protein A-Deficient Mice are Susceptible to Group B Streptococcal Infection.”The Journal of Immunology. vol. 158, pp. 4336-4340, 1997.
Thiel, S. et al., “Structures and Functions Associated with the group of mammalian lectins containing collagen-like sequences.”Federation of European Biochemical Societies. vol. 250, No. 1, pp. 78-84, 1989.
Coalson, Jacqueline J. et al. “Pathophysiologic, Morphometric, and Biochemical Studies of the Premature Baboon with Bronchopulmonary Dysplasia.”Am. Rev. Respir. Dis.vol. 145, pp. 872-881, 1992.
van Golde, L.M.G., ed., “Molecular Basis of Disease, Pulmonary surfactant.”Biochimica et Biophysica Acta, 1408, pp. 77-78, 1998.
Korfhagen Thomas R.
Levine Ann Marie
Steinhilber Wolfram
Whitsett Jeffrey A.
Altana Pharma AG
Goldberg Joshua B.
McGee Sheldon M.
Nashed Nashaat T.
Nath & Associates
LandOfFree
Recombinant SP-A for the treatment or prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant SP-A for the treatment or prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant SP-A for the treatment or prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3655960